Cargando…
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
We conducted a prospectively randomised clinical trial to investigate the role of adjuvant outpatient immunochemotherapy administered postoperatively in high-risk patients with renal cell carcinoma. In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified i...
Autores principales: | Atzpodien, J, Schmitt, E, Gertenbach, U, Fornara, P, Heynemann, H, Maskow, A, Ecke, M, Wöltjen, H H, Jentsch, H, Wieland, W, Wandert, T, Reitz, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361915/ https://www.ncbi.nlm.nih.gov/pubmed/15756254 http://dx.doi.org/10.1038/sj.bjc.6602443 |
Ejemplares similares
-
Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2006) -
Metastatic renal carcinoma comprehensive prognostic system
por: Atzpodien, J, et al.
Publicado: (2003) -
Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003) -
Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy
por: Akaba, Tomohiro, et al.
Publicado: (2021) -
MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)